Beyond post-marketing research and MedWatch: Long-term studies of drug risks

Critics of the drug safety system have discussed many different potential reforms, ranging from mandatory registration of clinical trials to increasing the power of regulatory agencies, but few have discussed one of the most important ways of enhancing safety: increasing the number of long-term studies of medications. Long-term studies of the risks and benefits of drugs can provide useful information for regulators, healthcare professionals, and patients. Government funding agencies should lead the effort to conduct long-term studies of drugs, but private companies should also be required to lend financial support. Because cost-effectiveness is likely to be an important consideration in conducting this research, funding agencies should focus, at first, on drugs that are used to treat common, chronic conditions.

• Publication year

  2007

• Venue

  Drug Design, Development and Therapy

• Publication date

  2007-09-24

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.2147/DDDT.S2352PMID 19727333PMCID 2763348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges in using observational studies to evaluate adverse effects of treatment.

  2007cited by this paper
• Class of antiretroviral drugs and the risk of myocardial infarction.

  2007cited by this paper
• Paying for drug approvals--who's using whom?

  2007cited by this paper
• Drug safety reform at the FDA--pendulum swing or systematic improvement?

  2007cited by this paper
• How the US drug safety system should be changed.

  2006cited by this paper
• Gaps in the Safety Net

  2005cited by this paper
• Drug safety. Gaps in the safety net.

  2005cited by this paper
• Safety in numbers--monitoring risk in approved drugs.

  2005cited by this paper
• Postmarketing surveillance--lack of vigilance, lack of trust.

  2004cited by this paper
• The Truth About the Drug Companies

  2004cited by this paper
• Setting Biomedical Research Priorities: Justice, Science, and Public Participation

  2001cited by this paper
• Helps decide on urgency

  1995cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Emerging horizons of AI in pharmaceutical research.

  2025cites this paper
• Vaccine Induced Autoimmunity May Cause Autism and Neurological Disorders

  2025cites this paper
• The evolution of integrated magnetic hyperthermia and chemodynamic therapy for combating cancer: a comprehensive viewpoint

  2025cites this paper
• Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials

  2025cites this paper
• Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines

  2024cites this paper
• A Commentary on “Pain Reduction and Improved Vascular Health Associated with Daily Consumption of an Anti-Inflammatory Dietary Supplement Blend” [Letter]

  2024cites this paper
• The therapeutic potential of sphingolipids for cardiovascular diseases

  2023cites this paper
• Long-term neurological cognitive, behavioral, functional, and quality of life outcomes after fetal myelomeningocele closure: a systematic review

  2022cites this paper
• Chemical Regulation

  2021cites this paper
• Proportionality in Public Health Regulation: The Case of Dietary Supplements

  2017cites this paper
• the safety of cns and non cns products for skin health current status and emerging plans for the future

  2016cites this paper
• Implementing Comparative Effectiveness Research in Primary Care

  2015cites this paper
• The Clinical Research of Nanomedicine: A New Ethical Challenge?

  2014cites this paper
• The Clinical Research of Nanomedicine: A New Ethical Challenge?

  2014cites this paper
• Postmarketing Research and Surveillance: Issues and Challenges.

  2008cites this paper